Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
810335
Approved small_molecule active
Quick answer
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] for Eosinophilic Esophagitis (EoE) is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Eosinophilic Esophagitis (EoE)
- Phase
- Approved
- Modality
- small_molecule
- Status
- active